Lotus Pharmaceutical Co., Ltd. (1795.TW)
TWD 220.5
(-3.08%)
TWD 220.5
(-3.08%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 4.9 Billion TWD | 13.51% |
| 2022 | 4.31 Billion TWD | 96.24% |
| 2021 | 2.2 Billion TWD | 34.43% |
| 2020 | 1.63 Billion TWD | 34.68% |
| 2019 | 1.21 Billion TWD | 170.95% |
| 2018 | 448.68 Million TWD | -14.22% |
| 2017 | 523.08 Million TWD | 114.04% |
| 2016 | 244.38 Million TWD | -45.55% |
| 2015 | 448.83 Million TWD | 203.12% |
| 2014 | -435.25 Million TWD | -1620.97% |
| 2013 | -25.29 Million TWD | 87.57% |
| 2012 | -203.4 Million TWD | -39.45% |
| 2011 | -145.86 Million TWD | -740.83% |
| 2010 | 22.76 Million TWD | -43.62% |
| 2009 | 40.37 Million TWD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 1.45 Billion TWD | 915.9% |
| 2024 Q2 | 1.63 Billion TWD | 12.11% |
| 2023 Q4 | 143.39 Million TWD | -91.55% |
| 2023 Q2 | 1.65 Billion TWD | 1.55% |
| 2023 Q3 | 1.69 Billion TWD | 2.31% |
| 2023 FY | 4.9 Billion TWD | 13.51% |
| 2023 Q1 | 1.63 Billion TWD | 298.75% |
| 2022 FY | 4.31 Billion TWD | 96.24% |
| 2022 Q3 | 2.73 Billion TWD | 435.43% |
| 2022 Q4 | 409.67 Million TWD | -85.02% |
| 2022 Q1 | 664.82 Million TWD | 68.12% |
| 2022 Q2 | 510.65 Million TWD | -23.19% |
| 2021 Q3 | 606.12 Million TWD | -0.58% |
| 2021 Q4 | 395.44 Million TWD | -34.76% |
| 2021 FY | 2.2 Billion TWD | 34.43% |
| 2021 Q1 | 718.55 Million TWD | 61.82% |
| 2021 Q2 | 609.65 Million TWD | -15.16% |
| 2020 Q1 | 291.98 Million TWD | 16.92% |
| 2020 Q4 | 444.05 Million TWD | 0.36% |
| 2020 Q2 | 417.53 Million TWD | 43.0% |
| 2020 Q3 | 442.47 Million TWD | 5.97% |
| 2020 FY | 1.63 Billion TWD | 34.68% |
| 2019 Q2 | 126.38 Million TWD | -71.65% |
| 2019 Q4 | 249.74 Million TWD | -14.37% |
| 2019 FY | 1.21 Billion TWD | 170.95% |
| 2019 Q1 | 445.84 Million TWD | 353.15% |
| 2019 Q3 | 291.65 Million TWD | 130.78% |
| 2018 Q2 | 100 Million TWD | 44.93% |
| 2018 FY | 448.68 Million TWD | -14.22% |
| 2018 Q4 | 98.38 Million TWD | -45.73% |
| 2018 Q3 | 181.29 Million TWD | 81.3% |
| 2018 Q1 | 69 Million TWD | -35.77% |
| 2017 Q2 | 167.72 Million TWD | 108.53% |
| 2017 FY | 523.08 Million TWD | 114.04% |
| 2017 Q4 | 107.43 Million TWD | -35.86% |
| 2017 Q1 | 80.43 Million TWD | 142.96% |
| 2017 Q3 | 167.5 Million TWD | -0.13% |
| 2016 Q1 | 148.31 Million TWD | 18.0% |
| 2016 Q4 | -187.2 Million TWD | -339.53% |
| 2016 Q3 | 78.15 Million TWD | -61.9% |
| 2016 FY | 244.38 Million TWD | -45.55% |
| 2016 Q2 | 205.12 Million TWD | 38.31% |
| 2015 FY | 448.83 Million TWD | 203.12% |
| 2015 Q3 | 162.05 Million TWD | 77.91% |
| 2015 Q4 | 125.68 Million TWD | -22.44% |
| 2015 Q2 | 91.08 Million TWD | 29.41% |
| 2015 Q1 | 70.38 Million TWD | 122.12% |
| 2014 Q1 | -65.82 Million TWD | -156.49% |
| 2014 Q4 | -318.19 Million TWD | -187.94% |
| 2014 Q3 | -110.5 Million TWD | 18.42% |
| 2014 Q2 | -135.45 Million TWD | -105.8% |
| 2014 FY | -435.25 Million TWD | -1620.97% |
| 2013 Q1 | 32.85 Million TWD | 148.47% |
| 2013 Q4 | -25.66 Million TWD | -51.32% |
| 2013 Q3 | -16.95 Million TWD | -9.21% |
| 2013 Q2 | -15.52 Million TWD | -147.26% |
| 2013 FY | -25.29 Million TWD | 87.57% |
| 2012 FY | -203.4 Million TWD | -39.45% |
| 2012 Q1 | -48.19 Million TWD | -101.31% |
| 2012 Q2 | -95.51 Million TWD | -98.19% |
| 2012 Q3 | 6.24 Million TWD | 106.54% |
| 2012 Q4 | -67.78 Million TWD | -1184.97% |
| 2011 Q1 | -4.96 Million TWD | -121.22% |
| 2011 Q2 | -54.21 Million TWD | -991.94% |
| 2011 Q3 | -62.74 Million TWD | -15.74% |
| 2011 Q4 | -23.93 Million TWD | 61.85% |
| 2011 FY | -145.86 Million TWD | -740.83% |
| 2010 Q3 | 5.71 Million TWD | -0.49% |
| 2010 Q2 | 5.74 Million TWD | 147.47% |
| 2010 Q1 | -12.09 Million TWD | 0.0% |
| 2010 Q4 | 23.4 Million TWD | 309.63% |
| 2010 FY | 22.76 Million TWD | -43.62% |
| 2009 FY | 40.37 Million TWD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Grape King Bio Ltd | 2.49 Billion TWD | -96.38% |
| Standard Chem & Pharm CO., LTD. | 1.25 Billion TWD | -289.261% |
| Maywufa Company Ltd. | 211.01 Million TWD | -2223.46% |
| ScinoPharm Taiwan, Ltd. | 314.49 Million TWD | -1459.009% |
| LIWANLI Innovation Co., Ltd. | - TWD | -Infinity% |
| YungShin Global Holding Corporation | 929.61 Million TWD | -427.418% |
| PhytoHealth Corporation | -121.67 Million TWD | 4129.473% |
| SCI Pharmtech, Inc. | 160.3 Million TWD | -2958.604% |
| Formosa Laboratories, Inc. | 674.97 Million TWD | -626.389% |
| PharmaEssentia Corporation | - TWD | -Infinity% |
| Bora Pharmaceuticals Co., LTD. | 5.24 Billion TWD | 6.595% |